{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:40:05Z","timestamp":1758937205735,"version":"3.44.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003074","name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["PICT 0440","PICT 0480","PID 0044"],"award-info":[{"award-number":["PICT 0440","PICT 0480","PID 0044"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010413","name":"Fundaci\u00f3n Ren\u00e9 Bar\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010413","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"publisher","award":["PIP 0056"],"award-info":[{"award-number":["PIP 0056"]}],"id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.leukres.2019.106221","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T11:42:04Z","timestamp":1567597324000},"page":"106221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The dynamic of TNF and IL6 gene expression in chronic myeloid leukemia patients reveals early responders to imatinib"],"prefix":"10.1016","volume":"86","author":[{"given":"Yesica","family":"Bestach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jazm\u00edn","family":"Toloza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Larripa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Belli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2019.106221_bib0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00277-015-2322-2","article-title":"A review of the European Leukemia Net recommendations for the management of CML","volume":"94","author":"Baccarani","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2019.106221_bib0010","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2141.2008.07433.x","article-title":"Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells","volume":"144","author":"Fei","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2019.106221_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101848","article-title":"Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients","volume":"9","author":"Giallongo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2019.106221_bib0020","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ajh.24096","article-title":"Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study","volume":"90","author":"Iriyama","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2019.106221_bib0025","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrclinonc.2016.41","article-title":"Immunological off-target effects of imatinib","volume":"13","author":"Zitvogel","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.leukres.2019.106221_bib0030","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3389\/fimmu.2015.00567","article-title":"Effector functions of natural killer cell subsets in the control of hematological malignancies","volume":"6","author":"Gismondi","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.leukres.2019.106221_bib0035","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","article-title":"Immune effector recovery in chronic myeloid leukemia and treatment-free remission","volume":"8","author":"Hughes","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.leukres.2019.106221_bib0040","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/416123","article-title":"The alteration and clinical significance of Th22\/Th17\/Th1 cells in patients with chronic myeloid leukemia","volume":"2015","author":"Chen","year":"2015","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.leukres.2019.106221_bib0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cellimm.2017.10.015","article-title":"The paradox of Th17 cell functions in tumor immunity","volume":"322","author":"Asadzadeh","year":"2017","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.leukres.2019.106221_bib0050","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1535-7163.MCT-14-0849","article-title":"The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses","volume":"14","author":"Christiansson","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.leukres.2019.106221_bib0055","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.106221_bib0060","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1182\/blood-2007-12-128397","article-title":"Development and dynamics of robust T-cell responses to CML under imatinib treatment","volume":"111","author":"Chen","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.106221_bib0065","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.3324\/haematol.2017.167080","article-title":"Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib","volume":"102","author":"Gullaksen","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2019.106221_bib0070","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/leu.2016.197","article-title":"Standardization of molecular monitoring for chronic myeloid leukemia in Latin America using locally produced secondary cellular calibrators","volume":"30","author":"Ruiz","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2019.106221_bib0075","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000458703","article-title":"Intracellular cytokines produced by stimulated CD3+ cells from chronic myeloid leukemia patients","volume":"137","author":"Ptackova","year":"2017","journal-title":"Acta Haematol."},{"key":"10.1016\/j.leukres.2019.106221_bib0080","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.leukres.2016.09.019","article-title":"Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli","volume":"50","author":"S\u00f6derlund","year":"2016","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2019.106221_bib0085","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3109\/10428194.2011.647017","article-title":"Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib","volume":"53","author":"Hayashi","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2019.106221_bib0090","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/leu.2016.34","article-title":"TGF-\u03b1 and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy","volume":"30","author":"Nievergall","year":"2016","journal-title":"Leukemia"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619301663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619301663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:59:28Z","timestamp":1758934768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212619301663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":18,"alternative-id":["S0145212619301663"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2019.106221","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The dynamic of TNF and IL6 gene expression in chronic myeloid leukemia patients reveals early responders to imatinib","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2019.106221","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106221"}}